search
INOVIO
Trends
- 1Inovio Wins First-Ever FDA Approval for a DNA Medicine▼Inovio Just Won the First FDA DNA Medicine Approval
Biotech company Inovio has secured the first FDA approval for a DNA-based medicine, marking a milestone for the field of genetic medicine. The decision opens the door to a new class of therapies built on DNA technology rather than traditional drugs or mRNA approaches. Investors and biotech watchers are closely tracking what the approval means for the company's future and for DNA medicine more broadly.
- 2Inovio Pharmaceuticals Stock Draws Investor Attention▼Inovio Pharmaceuticals, Inc. (INO) Stock Price, News, Quote & History
Inovio Pharmaceuticals (NASDAQ: INO) is seeing renewed attention on financial platforms, with its stock price, quotes, and historical performance being tracked by investors. The biotech company, known for developing DNA-based immunotherapies and vaccines, remains on watchlists as traders look for updates on its clinical pipeline and financial position. No specific new development was cited in the coverage.
- 3PGEN Stock Slides Premarket Ahead Of Earnings▼PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings
Precigen (PGEN) shares fell sharply in premarket trading, with retail investors speculating that the drop could open the door to a potential buyout. Discussion centers on competition from a rival biotech described as an Inovio competitor, with attention focused on the company's upcoming earnings report. Traders are divided on whether the weakness signals distress or an acquisition opportunity.
- 4FDA Grants Accelerated Approval to INOVIO's VOCERYQ for Recurrent Respiratory Papillomatosis▼INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
INOVIO says the US Food and Drug Administration has granted accelerated approval to VOCERYQ, an immunotherapy for adults with recurrent respiratory papillomatosis, a rare condition that causes recurring wart-like growths in the airway. The drug is approved to reduce how often patients need surgery to remove the growths. It marks a first approval for INOVIO, which has spent years developing DNA-based medicines without bringing a product to market.
- 5Traders Watch Pfizer, Inovio, SpaceX, Nvidia and Micron●$Pfizer (PFE.US)$$Inovio Pharmaceuticals (INO.US)$$SpaceX (SPCX.US)$$NVIDIA (NVDA.US)$$Micron Technology (MU.US)$
A bundle of tickers spanning pharma, space and semiconductors is circulating among market watchers, covering Pfizer, Inovio Pharmaceuticals, SpaceX, Nvidia and Micron Technology. The mix points to investors tracking healthcare, chip and commercial space names side by side, though no specific move or news event is attached to the listing itself.